Table 2 Primary and secondary endpoints of the study
From: Antimicrobial stewardship measures in cardiac surgery and its impact on surgical site infections
Endpoints of the study | Total | Cefuroxime | Cefazolin | p |
|---|---|---|---|---|
SSI total (%) | 37 (3.6) | 20 (3.4) | 17 (3.8) | 0.754 |
DSWI (%) | 18 (1.7) | 12 (2.1) | 6 (1.3) | 0.383 |
Vein harvesting site (%) | 17 (1.7) | 7 (1.2) | 10 (2.2) | 0.197 |
Urinary tract infections (%) | 40 (4.0) | 26 (4.6) | 14 (3.3) | 0.306 |
Pneumonia/trachebronchitis (%) | 70 (7.0) | 41 (7.1) | 29 (6.7) | 0.818 |
Sepsis (%) | 11 (1.1) | 8 (1.4) | 3 (0.7) | 0.294 |
Death (%) | 40 (3.9) | 19 (3.3) | 21 (4.7) | 0.238 |